Yes, I think that MRdian will remain in the game going forward. Keeping a lookout for any press releases from them is a way to be informed. My strategy is to give AS a chance for a year or two and see how it goes. I am also keeping a close eye on the progress of radiopharmaceutical research. The concept is the patient would receive an IV that contains 2 components. The first one seeks out the PSMA protein which is present in all prostate cancer cells. Once this is established, the second component enters the cancer cells and completely destroys their DNA preventing them from growing/spreading (think dead cells). This is accomplished with no damage to any healthy cells/tissue! This technique has already been used only on advanced prostate cancer patients with fairly good results and is FDA approved. More research, clinical trials and FDA approval will be needed before it's ready for us Low Risk persons. Educate yourself by reading these articles:
https://www.cancer.gov/news-events/cancer-currents-blog/2021/prostate-cancer-psma-radiopharmaceutical-vision

https://www.onclive.com/view/new-class-of-radiopharmaceutical-therapy-makes-headway-in-prostate-cancer#:~:text=PSMA-targeting%20small%20molecule%20inhibitors%20and%20mAbs%20are%20conjugated,Research%20groups%20in%20Germany%20initially%20developed%20both%20therapies.
As you can see, a solution may be just around the corner for us. The second article talks about mCRPC which is Metastatic Castration-Resistant Prostate Cancer. Then talks about mAbs which are monoclonal antibodies.